279 related articles for article (PubMed ID: 22856540)
1. Medication adherence and utilization in patients with schizophrenia or bipolar disorder receiving aripiprazole, quetiapine, or ziprasidone at hospital discharge: a retrospective cohort study.
Berger A; Edelsberg J; Sanders KN; Alvir JM; Mychaskiw MA; Oster G
BMC Psychiatry; 2012 Aug; 12():99. PubMed ID: 22856540
[TBL] [Abstract][Full Text] [Related]
2. Healthcare costs associated with treatment of bipolar disorder using a mood stabilizer plus adjunctive aripiprazole, quetiapine, risperidone, olanzapine or ziprasidone.
Jing Y; Kim E; You M; Pikalov A; Tran QV
J Med Econ; 2009 Jun; 12(2):104-13. PubMed ID: 19527195
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of second-generation antipsychotic medications in early-onset schizophrenia.
Olfson M; Gerhard T; Huang C; Lieberman JA; Bobo WV; Crystal S
Schizophr Bull; 2012 Jun; 38(4):845-53. PubMed ID: 21307041
[TBL] [Abstract][Full Text] [Related]
4. An evaluation of inpatient treatment continuation and hospital readmission rates in patients with bipolar disorder treated with aripiprazole or quetiapine.
Kreys TJ; Fabian TJ; Saul MI; Haskett R; Coley KC
J Psychiatr Pract; 2013 Jul; 19(4):288-95. PubMed ID: 23852103
[TBL] [Abstract][Full Text] [Related]
5. Comparison of metabolic effects of aripiprazole, quetiapine and ziprasidone after 12 weeks of treatment in first treated episode of psychosis.
Pérez-Iglesias R; Ortiz-Garcia de la Foz V; Martínez García O; Amado JA; Garcia-Unzueta MT; Ayesa-Arriola R; Suarez-Pinilla P; Tabares-Seisdedos R; Crespo-Facorro B
Schizophr Res; 2014 Oct; 159(1):90-4. PubMed ID: 25151200
[TBL] [Abstract][Full Text] [Related]
6. Risk of arrest in persons with schizophrenia and bipolar disorder in a Florida Medicaid program: the role of atypical antipsychotics, conventional neuroleptics, and routine outpatient behavioral health services.
Van Dorn RA; Andel R; Boaz TL; Desmarais SL; Chandler K; Becker MA; Howe A
J Clin Psychiatry; 2011 Apr; 72(4):502-8. PubMed ID: 21527125
[TBL] [Abstract][Full Text] [Related]
7. Treatment of first-episode non-affective psychosis: a randomized comparison of aripiprazole, quetiapine and ziprasidone over 1 year.
Crespo-Facorro B; de la Foz VO; Mata I; Ayesa-Arriola R; Suarez-Pinilla P; Valdizan EM; Martinez-Garcia O; Pérez-Iglesias R
Psychopharmacology (Berl); 2014 Jan; 231(2):357-66. PubMed ID: 23958945
[TBL] [Abstract][Full Text] [Related]
8. Treatment adherence among patients with bipolar or manic disorder taking atypical and typical antipsychotics.
Gianfrancesco FD; Rajagopalan K; Sajatovic M; Wang RH
J Clin Psychiatry; 2006 Feb; 67(2):222-32. PubMed ID: 16566617
[TBL] [Abstract][Full Text] [Related]
9. Quetiapine versus other atypical antipsychotics for schizophrenia.
Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
[TBL] [Abstract][Full Text] [Related]
10. Comparing the effectiveness of aripiprazole and quetiapine in schizophrenia and related psychoses: a naturalistic, retrospective chart review study.
Shajahan P; Keith S; Majjiga C; Murphy J; MacRae A; Bashir M; Taylor M
J Clin Psychiatry; 2009 May; 70(5):692-8. PubMed ID: 19284930
[TBL] [Abstract][Full Text] [Related]
11. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems.
Mukundan A; Faulkner G; Cohn T; Remington G
Cochrane Database Syst Rev; 2010 Dec; (12):CD006629. PubMed ID: 21154372
[TBL] [Abstract][Full Text] [Related]
12. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia.
Mullins CD; Obeidat NA; Cuffel BJ; Naradzay J; Loebel AD
Schizophr Res; 2008 Jan; 98(1-3):8-15. PubMed ID: 17596914
[TBL] [Abstract][Full Text] [Related]
13. Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: a post-hoc analysis of 5 double-blind, randomized clinical trials.
Stauffer V; Ascher-Svanum H; Liu L; Ball T; Conley R
BMC Psychiatry; 2009 Mar; 9():13. PubMed ID: 19335905
[TBL] [Abstract][Full Text] [Related]
14. Aripiprazole, ziprasidone, and quetiapine in the treatment of first-episode nonaffective psychosis: results of a 6-week, randomized, flexible-dose, open-label comparison.
Crespo-Facorro B; Pérez-Iglesias R; Mata I; Ortiz-Garcia de la Foz V; Martínez-Garcia O; Valdizan EM; Vazquez-Barquero JL
J Clin Psychopharmacol; 2013 Apr; 33(2):215-20. PubMed ID: 23422371
[TBL] [Abstract][Full Text] [Related]
15. How dosing of ziprasidone in a state hospital system differs from product labeling.
Citrome L; Jaffe A; Levine J
J Clin Psychiatry; 2009 Jul; 70(7):975-82. PubMed ID: 19653974
[TBL] [Abstract][Full Text] [Related]
16. Aripiprazole, Ziprasidone and Quetiapine in the treatment of first-episode nonaffective psychosis: a 12-week randomized, flexible-dose, open-label trial.
Crespo-Facorro B; Ortiz-García de la Foz V; Mata I; Ayesa-Arriola R; Suarez-Pinilla P; Valdizan EM; Vázquez-Barquero JL; Pérez-Iglesias R
Schizophr Res; 2013 Jul; 147(2-3):375-82. PubMed ID: 23643328
[TBL] [Abstract][Full Text] [Related]
17. Does antipsychotic polypharmacy increase the risk for metabolic syndrome?
Correll CU; Frederickson AM; Kane JM; Manu P
Schizophr Res; 2007 Jan; 89(1-3):91-100. PubMed ID: 17070017
[TBL] [Abstract][Full Text] [Related]
18. Health-related quality of life among patients treated with lurasidone: results from a switch trial in patients with schizophrenia.
Awad G; Hassan M; Loebel A; Hsu J; Pikalov A; Rajagopalan K
BMC Psychiatry; 2014 Feb; 14():53. PubMed ID: 24559217
[TBL] [Abstract][Full Text] [Related]
19. Long-term metabolic effects of aripiprazole, ziprasidone and quetiapine: a pragmatic clinical trial in drug-naïve patients with a first-episode of non-affective psychosis.
Vázquez-Bourgon J; Pérez-Iglesias R; Ortiz-García de la Foz V; Suárez Pinilla P; Díaz Martínez Á; Crespo-Facorro B
Psychopharmacology (Berl); 2018 Jan; 235(1):245-255. PubMed ID: 29075885
[TBL] [Abstract][Full Text] [Related]
20. The ARIQUELI study: potentiation of quetiapine in bipolar I nonresponders with lithium versus aripiprazole.
Missio G; Moreno DH; Fernandes F; Bio DS; Soeiro-de-Souza MG; Rodrigues dos Santos D; David DP; Costa LF; Demétrio FN; Moreno RA
Trials; 2013 Jun; 14():190. PubMed ID: 23805994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
